| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Gadoteridol (SQ-32692; Gd-HP-DO3A) is a novel and potent gadolinium-based magnetic resonance imaging (MRI) contrast agent that can be used in the imaging of the central nervous system. Contrast agents are commonly used in combination with magnetic resonance imaging (MRI) to monitor the distribution of molecules in the brain.
| ln Vivo |
In the rat hippocampal region, a single intracerebral injection of gadoteridol (1 mM) increases rAAV1 distribution [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rats (3 -5 months) [1]
Doses: 1 mM/rat Route of Administration: Intracerebral injection once, co-infusion with rAAV1 or AAV5 Experimental Results: Increased transduction efficiency of AAV1, But AAV5 is not added. |
| References |
[1]. Hullinger R, et al. The MRI contrast agent gadoteridol enhances distribution of rAAV1 in the rat hippocampus. Gene Ther. 2013 Dec;20(12):1172-7.
|
| Molecular Formula |
C₁₇H₂₈GDN₄O₇
|
|---|---|
| Molecular Weight |
557.68
|
| CAS # |
120066-54-8
|
| Related CAS # |
Gadoteridol pentahydrate
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CC1O[Gd+3]2([N]3(CC4)CC5=O)([N]6(CC7)CC([O-]2)=O)([N]47CC8=O)([O-]8)([O-]5)[N](CC6)(CC3)C1
|
| Synonyms |
SQ-32692SQ32692 Gd-HP-DO3A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 280 mg/mL (~502.08 mM)
DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (179.31 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7931 mL | 8.9657 mL | 17.9314 mL | |
| 5 mM | 0.3586 mL | 1.7931 mL | 3.5863 mL | |
| 10 mM | 0.1793 mL | 0.8966 mL | 1.7931 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
